<PAGE>

                                                                     EXHIBIT 4.2

                            CARDIOGENESIS CORPORATION

                          SECURITIES PURCHASE AGREEMENT

                                OCTOBER 26, 2004

<PAGE>

                          SECURITIES PURCHASE AGREEMENT

      THIS SECURITIES PURCHASE AGREEMENT (this "Agreement") is made and entered
into as of October 26, 2004, by and between CARDIOGENESIS CORPORATION, a
California corporation (the "Company"), and Laurus Master Fund, Ltd., a Cayman
Islands company (the "Purchaser").

                                    RECITALS

      WHEREAS, the Company has authorized the sale to the Purchaser of a
Convertible Term Note in the aggregate principal amount of Six Million Dollars
($6,000,000) (as amended, modified or supplemented from time to time, the
"Note"), which Note is convertible into shares of the Company's common stock, no
par value (the "Common Stock") at an initial fixed conversion price of $0.50 per
share of Common Stock ("Fixed Conversion Price");

      WHEREAS, the Company wishes to issue a warrant to the Purchaser to
purchase up to 2,640,000 shares of the Company's Common Stock (subject to
adjustment as set forth therein) in connection with Purchaser's purchase of the
Note;

      WHEREAS, Purchaser desires to purchase the Note and the Warrant (as
defined in Section 2) on the terms and conditions set forth herein; and

      WHEREAS, the Company desires to issue and sell the Note and Warrant to
Purchaser on the terms and conditions set forth herein.

                                    AGREEMENT

      NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
promises, representations, warranties and covenants hereinafter set forth and
for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto agree as follows:

      1. Agreement to Sell and Purchase. Pursuant to the terms and conditions
set forth in this Agreement, on the Closing Date (as defined in Section 3), the
Company agrees to sell to the Purchaser, and the Purchaser hereby agrees to
purchase from the Company a Note in the aggregate principal amount of
$6,000,0000 convertible in accordance with the terms thereof into shares of the
Company's Common Stock in accordance with the terms of the Note and this
Agreement. The offer and sale of the Note purchased on the Closing Date shall be
known as the "Offering." A form of the Note is annexed hereto as Exhibit A. The
Note will mature on the Maturity Date (as defined in the Note). Collectively,
the Note and Warrant and Common Stock issuable in payment of the Note, upon
conversion of the Note and upon exercise of the Warrant (and shares of the
Company's Common Stock issuable upon exercise of the Warrant (the "Warrant
Shares")) are referred to as the "Securities."

      2. Fees and Warrant. On the Closing Date:

            (a) The Company will issue and deliver to the Purchaser a Warrant to
      purchase up to 2,640,000 shares of Common Stock in connection with the
      Offering (as

<PAGE>

      amended, modified or supplemented from time to time, the "Warrant")
      pursuant to Section 1 hereof. The Warrant must be delivered on the Closing
      Date. A form of Warrant is annexed hereto as Exhibit B. All the
      representations, covenants, warranties, undertakings, and indemnification,
      and other rights made or granted to or for the benefit of the Purchaser by
      the Company are hereby also made and granted in respect of the issuance of
      the Warrant (but not with respect to any future exercise thereof).

            (b) Subject to the terms of Section 2(d) below, the Company shall
      pay to Laurus Capital Management, LLC, manager of the Purchaser a closing
      payment in an amount equal to three and six tenths percent (3.60%) of the
      aggregate principal amount of the Note. The foregoing fee is referred to
      herein as the "Closing Payment."

            (c) The Company shall reimburse the Purchaser for its actual
      expenses (including legal fees and expenses) incurred in connection with
      the preparation and negotiation of this Agreement and the Related
      Agreements (as hereinafter defined), and actual expenses incurred in
      connection with the Purchaser's due diligence review of the Company and
      its Subsidiaries (as defined in Section 6.8) and all related matters. Net
      amounts required to be paid under this Section 2(c) will be paid on the
      Closing Date and shall not exceed $29,500.

            (d) The Closing Payment and the expenses referred to in the
      preceding clause (c) (net of deposits previously paid by the Company)
      shall be paid at closing out of funds held pursuant to the Escrow
      Agreement (as defined below) and a disbursement letter (the "Disbursement
      Letter").

      3. Closing, Delivery and Payment.

            3.1 Closing. Subject to the terms and conditions herein, the closing
of the transactions contemplated hereby (the "Closing"), shall take place on the
date hereof, at such time or place as the Company and Purchaser may mutually
agree (such date is hereinafter referred to as the "Closing Date").

            3.2 Delivery. Pursuant to the Escrow Agreement, at the Closing on
the Closing Date, the Company will deliver to the Purchaser, among other things,
a Note in the form attached as Exhibit A representing the principal amount of
$6,000,000 and a Warrant in the form attached as Exhibit B in the Purchaser's
name representing the right to purchase up to 2,640,000 Warrant Shares and the
Purchaser will deliver to the Company, among other things, the amounts set forth
in the Disbursement Letter by certified funds or wire transfer (it being
understood that $2,877,250 of the proceeds of the Note shall be placed in the
Restricted Account (as defined in the Restricted Account Agreement referred to
below)).

      4. Representations and Warranties of the Company. The Company hereby
represents and warrants to the Purchaser as follows (which representations and
warranties are supplemented by, and subject to, (i) any disclosure contained in
the Company's filings under the Securities Exchange Act of 1934 made prior to
the date of this Agreement (collectively, the "Exchange Act Filings"), copies of
which have been provided to the Purchaser, and (ii) any exceptions disclosed in
the Disclosure Schedules attached hereto as Exhibit E:

<PAGE>

            4.1 Organization, Good Standing and Qualification. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of its jurisdiction of organization. The Company has the corporate power and
authority to own and operate its properties and assets, to execute and deliver
this (i) this Agreement, (ii) the Note and the Warrant to be issued in
connection with this Agreement, (iii) the Master Security Agreement dated as of
the date hereof between the Company and the Purchaser (as amended, modified or
supplemented from time to time, the "Master Security Agreement"), (iv) the
Registration Rights Agreement relating to the Securities dated as of the date
hereof between the Company and the Purchaser (as amended, modified or
supplemented from time to time, the "Registration Rights Agreement"), (v) the
Funds Escrow Agreement dated as of the date hereof among the Company, the
Purchaser and the escrow agent referred to therein, substantially in the form of
Exhibit D hereto (as amended, modified or supplemented from time to time, the
"Escrow Agreement"), (vi) the Restricted Account Agreement dated as of the date
hereof among the Company, the Purchaser and North Fork Bank (as amended,
modified or supplemented from time to time, the "Restricted Account Agreement"),
(vii) the Restricted Account Side Letter related to the Restricted Account
Agreement dated as of the date hereof between the Company and the Purchaser (as
amended, modified or supplemented from time to time, the "Restricted Account
Side Letter") and (viii) all other agreements related to this Agreement and the
Note and referred to herein (the preceding clauses (ii) through (viii),
collectively, the "Related Agreements"), to issue and sell the Note and the
shares of Common Stock issuable upon conversion of the Note (the "Note Shares"),
to issue and sell the Warrant and the Warrant Shares, and to carry out the
provisions of this Agreement and the Related Agreements and to carry on its
business as presently conducted. The Company is duly qualified and is authorized
to do business and is in good standing as a foreign corporation in all
jurisdictions in which such qualification or authorization is required, except
for those jurisdictions in which the failure to do so has not had, or could not
reasonably be expected to have, individually or in the aggregate, a material
adverse effect on the business, assets, liabilities, condition (financial or
otherwise), properties, operations or prospects of the Company (a "Material
Adverse Effect").

            4.2 Subsidiaries. Each direct and indirect Subsidiary of the
Company, the direct owner of such Subsidiary and its percentage ownership
thereof, is set forth on Schedule 4.2. For the purpose of this Agreement, a
"Subsidiary" of any person or entity means (i) a corporation or other entity
whose shares of stock or other ownership interests having ordinary voting power
(other than stock or other ownership interests having such power only by reason
of the happening of a contingency) to elect a majority of the directors of such
corporation, or other persons or entities performing similar functions for such
person or entity, are owned, directly or indirectly, by such person or entity or
(ii) a corporation or other entity in which such person or entity owns, directly
or indirectly, more than 50% of the equity interests at such time.

            4.3 Capitalization; Voting Rights.

            (a) The authorized capital stock of the Company, as of the date
      hereof, consists of 80,000,000 shares, of which 75,000,000 are shares of
      Common Stock, no par value, 41,388,994 shares of which are issued and
      outstanding, and 5,000,000 are shares of preferred stock, no par value,
      none of which shares of preferred stock are issued and outstanding.

<PAGE>

            (b) Except as disclosed on Schedule 4.3, other than: (i) the shares
      reserved for issuance under the Company's stock option plans; and (ii)
      shares which may be issued pursuant to this Agreement and the Related
      Agreements, there are no outstanding options, warrants, rights (including
      conversion or preemptive rights and rights of first refusal), proxy or
      stockholder agreements, or arrangements or agreements of any kind for the
      purchase or acquisition from the Company of any of its securities. Except
      as disclosed on Schedule 4.3, neither the offer, issuance or sale of any
      of the Note or Warrant, or the issuance of any of the Note Shares or
      Warrant Shares, nor the consummation of any transaction contemplated
      hereby will result in a change in the price or number of any securities of
      the Company outstanding, under anti-dilution or other similar provisions
      contained in or affecting any such securities.

            (c) All issued and outstanding shares of the Company's Common Stock:
      (i) have been duly authorized and validly issued and are fully paid and
      nonassessable; and (ii) were issued in compliance with all applicable
      state and federal laws concerning the issuance of securities.

            (d) The rights, preferences, privileges and restrictions of the
      shares of the Common Stock are as stated in the Company's Articles of
      Incorporation (the "Charter"). The Note Shares and Warrant Shares have
      been duly and validly reserved for issuance. When issued and paid for in
      compliance with the provisions of this Agreement and the Company's
      Charter, and as applicable, the Note and the Warrant, the Securities will
      be validly issued, fully paid and nonassessable, and will be free of any
      liens or encumbrances; provided, however, that the Securities may be
      subject to restrictions on transfer under state and/or federal securities
      laws as set forth herein or as otherwise required by such laws at the time
      a transfer is proposed.

            4.4 Authorization; Binding Obligations. All corporate action on the
part of the Company, its officers and directors necessary for the authorization
of this Agreement and the Related Agreements, the performance of all obligations
of the Company hereunder and under the Related Agreements at the Closing and,
the authorization, sale, issuance and delivery of the Note and Warrant has been
taken or will be taken prior to the Closing. This Agreement and the Related
Agreements, when executed and delivered and to the extent it is a party thereto,
will be valid and binding obligations of the Company enforceable in accordance
with their terms, except:

            (a) as limited by applicable bankruptcy, insolvency, reorganization,
      moratorium or other laws of general application affecting enforcement of
      creditors' rights; and

            (b) general principles of equity that restrict the availability of
      equitable or legal remedies.

The sale of the Note and the subsequent conversion of the Note into Note Shares
are not and will not be subject to any preemptive rights or rights of first
refusal that have not been properly waived or complied with. The issuance of the
Warrant and the subsequent exercise of the

<PAGE>

Warrant for Warrant Shares are not and will not be subject to any preemptive
rights or rights of first refusal that have not been properly waived or complied
with.

            4.5 Liabilities. The Company does not have any contingent
liabilities, except current liabilities incurred in the ordinary course of
business and liabilities disclosed in any Exchange Act Filings or the Disclosure
Schedules.

            4.6 Agreements; Action. Except as set forth on Schedule 4.6 or as
disclosed in any Exchange Act Filings:

            (a) There are no agreements, understandings, instruments, contracts,
      proposed transactions, judgments, orders, writs or decrees to which the
      Company is a party or to its knowledge by which it is bound which may
      involve: (i) obligations (contingent or otherwise) of, or payments to, the
      Company in excess of $50,000 (other than obligations of, or payments to,
      the Company arising from purchase, sale, or licensing agreements entered
      into in the ordinary course of business); or (ii) the transfer or license
      of any patent, copyright, trade secret or other proprietary right to or
      from the Company (other than licenses arising from the purchase of "off
      the shelf" or other standard products or arising from transactions entered
      into in the ordinary course of the Company's business); or (iii)
      provisions restricting the development, manufacture or distribution of the
      Company's products or services; or (iv) indemnification by the Company
      with respect to infringements of proprietary rights, other than the
      indemnification provisions contained in the purchase or sale agreements
      entered into in the ordinary course of business of the Company.

            (b) Since December 31, 2003, the Company has not: (i) declared or
      paid any dividends, or authorized or made any distribution upon or with
      respect to any class or series of its capital stock; (ii) incurred any
      indebtedness for money borrowed or any other liabilities (other than
      ordinary course obligations) individually in excess of $50,000 or, in the
      case of indebtedness and/or liabilities individually less than $50,000, in
      excess of $100,000 in the aggregate; (iii) made any loans or advances to
      any person not in excess, individually or in the aggregate, of $100,000,
      other than ordinary advances for travel expenses; or (iv) sold, exchanged
      or otherwise disposed of any of its assets or rights, other than the sale
      of its inventory in the ordinary course of business.

            (c) For the purposes of subsections (a) and (b) above, all
      indebtedness, liabilities, agreements, understandings, instruments,
      contracts and proposed transactions involving the same person or entity
      (including persons or entities the Company has reason to believe are
      affiliated therewith) shall be aggregated for the purpose of meeting the
      individual minimum dollar amounts of such subsections.

            4.7 Obligations to Related Parties. Except as set forth on Schedule
4.7, there are no obligations of the Company to officers, directors,
stockholders or employees of the Company other than:

            (a) for payment of salary for services rendered and for bonus
      payments;

<PAGE>

            (b) reimbursement for reasonable expenses incurred on behalf of the
      Company;

            (c) for other standard employee benefits made generally available to
      all employees (including stock option agreements outstanding under any
      stock option plan approved by the Board of Directors of the Company); and

            (d) obligations listed in the Company's financial statements or
      disclosed in any of its Exchange Act Filings.

Except as described above or set forth on Schedule 4.7, none of the officers,
directors or, to the best of the Company's knowledge, key employees or
stockholders of the Company or any members of their immediate families, are
indebted to the Company, individually or in the aggregate, in excess of $50,000
or have any direct or indirect ownership interest in any firm or corporation
with which the Company is affiliated or with which the Company has a business
relationship, or any firm or corporation which competes with the Company, other
than passive investments in publicly traded companies (representing less than
one percent (1%) of such company) which may compete with the Company. Except as
described above, no officer, director or stockholder, or any member of their
immediate families, is, directly or indirectly, interested in any material
contract with the Company and no agreements, understandings or proposed
transactions are contemplated between the Company and any such person. Except as
set forth on Schedule 4.7, the Company is not a guarantor or indemnitor of any
indebtedness of any other person, firm or corporation.

            4.8 Changes. Since December 31, 2003, except as disclosed in any
Exchange Act Filing or in any Schedule to this Agreement or to any of the
Related Agreements, there has not been:

            (a) any change in the business, assets, liabilities, condition
      (financial or otherwise), properties, operations or prospects of the
      Company, which, individually or in the aggregate, has had or could
      reasonably be expected to have, a Material Adverse Effect;

            (b) any resignation or termination of any officer, key employee or
      group of employees of the Company;

            (c) any material change, except in the ordinary course of business,
      in the contingent obligations of the Company by way of guaranty,
      endorsement, indemnity, warranty or otherwise;

            (d) any damage, destruction or loss, whether or not covered by
      insurance, which has had, or could reasonably be expected to have,
      individually or in the aggregate, a Material Adverse Effect;

            (e) any waiver by the Company of a valuable right or of a material
      debt owed to it;

<PAGE>

            (f) any direct or indirect material loans made by the Company to any
      stockholder, employee, officer or director of the Company, other than
      advances made in the ordinary course of business;

            (g) any material change in any compensation arrangement or agreement
      with any employee, officer, director or stockholder;

            (h) any declaration or payment of any dividend or other distribution
      of the assets of the Company;

            (i) any labor organization activity related to the Company;

            (j) any debt, obligation or liability incurred, assumed or
      guaranteed by the Company, except those for immaterial amounts and for
      current liabilities incurred in the ordinary course of business;

            (k) any sale, assignment or transfer of any patents, trademarks,
      copyrights, trade secrets or other intangible assets;

            (l) any change in any material agreement to which the Company is a
      party or by which it is bound which, either individually or in the
      aggregate, has had, or could reasonably be expected to have, a Material
      Adverse Effect;

            (m) any other event or condition of any character that, either
      individually or in the aggregate, has had, or could reasonably be expected
      to have, a Material Adverse Effect; or

            (n) any arrangement or commitment by the Company to do any of the
      acts described in subsection (a) through (m) above.

            4.9 Title to Properties and Assets; Liens, Etc. Except as set forth
on Schedule 4.9, the Company has good and marketable title to its properties and
assets, and good title to its leasehold estates, in each case subject to no
mortgage, pledge, lien, lease, encumbrance or charge, other than:

            (a) those resulting from taxes which have not yet become delinquent;

            (b) minor liens and encumbrances which do not materially detract
      from the value of the property subject thereto or materially impair the
      operations of the Company; and

            (c) those that have otherwise arisen in the ordinary course of
      business.

All facilities, machinery, equipment, fixtures, vehicles and other properties
owned, leased or used by the Company are in good operating condition and repair
and are reasonably fit and usable for the purposes for which they are being
used. Except as set forth on Schedule 4.9, the Company is in compliance with all
material terms of each lease to which it is a party or is otherwise bound.

<PAGE>

            4.10 Intellectual Property.

            (a) The Company owns or possesses sufficient legal rights to all
      patents, trademarks, service marks, trade names, copyrights, trade
      secrets, licenses, information and other proprietary rights and processes
      necessary for its business as now conducted and to the Company's knowledge
      as presently proposed to be conducted (the "Intellectual Property"),
      without any known infringement of the rights of others. There are no
      outstanding options, licenses or agreements of any kind relating to the
      foregoing proprietary rights, nor is the Company bound by or a party to
      any options, licenses or agreements of any kind with respect to the
      patents, trademarks, service marks, trade names, copyrights, trade
      secrets, licenses, information and other proprietary rights and processes
      of any other person or entity other than such licenses or agreements
      arising from the purchase of "off the shelf" or standard products.

            (b) The Company has not received any communications alleging that
      the Company has violated any of the patents, trademarks, service marks,
      trade names, copyrights or trade secrets or other proprietary rights of
      any other person or entity, nor is the Company aware of any basis
      therefor.

            (c) The Company does not believe it is or will be necessary to
      utilize any inventions, trade secrets or proprietary information of any of
      its employees made prior to their employment by the Company, except for
      inventions, trade secrets or proprietary information that have been
      rightfully assigned to the Company.

            4.11 Compliance with Other Instruments. The Company is not in
violation or default of (x) any term of its Charter or Bylaws, or (y) of any
provision of any indebtedness, mortgage ,indenture, contract, agreement or
instrument to which it is party or by which it is bound or of any judgment,
decree, order or writ, which violation or default, in the case of this clause
(y), has had, or could reasonably be expected to have, either individually or in
the aggregate, a Material Adverse Effect. The execution, delivery and
performance of and compliance with this Agreement and the Related Agreements to
which it is a party, and the issuance and sale of the Note by the Company and
the other Securities by the Company each pursuant hereto and thereto, will not,
with or without the passage of time or giving of notice, result in any such
material violation, or be in conflict with or constitute a default under any
such term or provision, or result in the creation of any mortgage, pledge, lien,
encumbrance or charge upon any of the properties or assets of the Company or the
suspension, revocation, impairment, forfeiture or nonrenewal of any permit,
license, authorization or approval applicable to the Company, its business or
operations or any of its assets or properties.

            4.12 Litigation. Except as set forth on Schedule 4.12 hereto, there
is no action, suit, proceeding or investigation pending or, to the Company's
knowledge, currently threatened against the Company that prevents the Company
from entering into this Agreement or the Related Agreements, or from
consummating the transactions contemplated hereby or thereby, or which has had,
or could reasonably be expected to have, either individually or in the
aggregate, a Material Adverse Effect or could result in any change in the
current equity ownership of the Company, nor is the Company aware that there is
any basis to assert any of the foregoing. The Company is not a party or subject
to the provisions of any order, writ, injunction, judgment or

<PAGE>

decree of any court or government agency or instrumentality. There is no action,
suit, proceeding or investigation by the Company currently pending or which the
Company intends to initiate.

            4.13 Tax Returns and Payments. The Company has timely filed all tax
returns (federal, state and local) required to be filed by it. All taxes shown
to be due and payable on such returns, any assessments imposed, and all other
taxes due and payable by the Company on or before the Closing, have been paid or
will be paid prior to the time they become delinquent. Except as set forth on
Schedule 4.13, the Company has not been advised:

            (a) that any of its returns, federal, state or other, have been or
      are being audited as of the date hereof; or

            (b) of any deficiency in assessment or proposed judgment to its
      federal, state or other taxes.

The Company has no knowledge of any liability of any tax to be imposed upon its
properties or assets as of the date of this Agreement that is not adequately
provided for.

            4.14 Employees. Except as set forth on Schedule 4.14, the Company
has no collective bargaining agreements with any of its employees. There is no
labor union organizing activity pending or, to the Company's knowledge,
threatened with respect to the Company. Except as disclosed in the Exchange Act
Filings or on Schedule 4.14, the Company is not a party to or bound by any
currently effective employment contract, deferred compensation arrangement,
bonus plan, incentive plan, profit sharing plan, retirement agreement or other
employee compensation plan or agreement which would be required to be disclosed
or attached as Exhibits to reports filed under the Exchange Act. To the
Company's knowledge, no employee of the Company, nor any consultant with whom
the Company has contracted, is in violation of any term of any employment
contract, proprietary information agreement or any other agreement relating to
the right of any such individual to be employed by, or to contract with, the
Company because of the nature of the business to be conducted by the Company;
and to the Company's knowledge the continued employment by the Company of its
present employees, and the performance of the Company's contracts with its
independent contractors, will not result in any such violation. The Company is
not aware that any of its employees is obligated under any contract (including
licenses, covenants or commitments of any nature) or other agreement, or subject
to any judgment, decree or order of any court or administrative agency, that
would interfere with their duties to the Company. The Company has not received
any notice alleging that any such violation has occurred. Except for employees
who have a current effective employment agreement with the Company, no employee
of the Company has been granted the right to continued employment by the Company
or to any material compensation following termination of employment with the
Company. Except as set forth on Schedule 4.14, the Company is not aware that any
officer, key employee or group of employees intends to terminate his, her or
their employment with the Company, nor does the Company have a present intention
to terminate the employment of any officer, key employee or group of employees.

            4.15 Registration Rights and Voting Rights. Except as set forth on
Schedule 4.15 and except as disclosed in Exchange Act Filings, the Company is
presently not under any

<PAGE>

obligation, and has not granted any rights, to register any of the Company's
presently outstanding securities or any of its securities that may hereafter be
issued. Except as set forth on Schedule 4.15 and except as disclosed in Exchange
Act Filings, to the Company's knowledge, no stockholder of the Company has
entered into any agreement with respect to the voting of equity securities of
the Company.

            4.16 Compliance with Laws; Permits. The Company is not in violation
of any applicable statute, rule, regulation, order or restriction of any
domestic or foreign government or any instrumentality or agency thereof in
respect of the conduct of its business or the ownership of its properties which
has had, or could reasonably be expected to have, either individually or in the
aggregate, a Material Adverse Effect. No governmental orders, permissions,
consents, approvals or authorizations are required to be obtained and no
registrations or declarations are required to be filed in connection with the
execution and delivery of this Agreement or any Related Agreement and the
issuance of any of the Securities, except such as has been duly and validly
obtained or filed, or with respect to any filings that must be made after the
Closing, as will be filed in a timely manner. The Company has all material
franchises, permits, licenses and any similar authority necessary for the
conduct of its business as now being conducted by it, the lack of which could,
either individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.

            4.17 Environmental and Safety Laws. The Company is not in violation
of any applicable statute, law or regulation relating to the environment or
occupational health and safety, and to its knowledge, no material expenditures
are or will be required in order to comply with any such existing statute, law
or regulation. Except as set forth on Schedule 4.17, no Hazardous Materials (as
defined below) are used or have been used, stored, or disposed of by the Company
or, to the Company's knowledge, by any other person or entity on any property
owned, leased or used by the Company. For the purposes of the preceding
sentence, "Hazardous Materials" shall mean:

            (a) materials which are listed or otherwise defined as "hazardous"
      or "toxic" under any applicable local, state, federal and/or foreign laws
      and regulations that govern the existence and/or remedy of contamination
      on property, the protection of the environment from contamination, the
      control of hazardous wastes, or other activities involving hazardous
      substances, including building materials; or

            (b) any petroleum products or nuclear materials.

            4.18 Valid Offering. Assuming the accuracy of the representations
and warranties of the Purchaser contained in this Agreement, the offer, sale and
issuance of the Securities will be exempt from the registration requirements of
the Securities Act of 1933, as amended (the "Securities Act"), and will have
been registered or qualified (or are exempt from registration and qualification)
under the registration, permit or qualification requirements of all applicable
state securities laws.

            4.19 Full Disclosure. Neither this Agreement, the Related Agreements
nor the exhibits and schedules hereto and thereto nor any other document
delivered by the Company to Purchaser or its attorneys or agents in connection
herewith or therewith or with the transactions

<PAGE>

contemplated hereby or thereby, when viewed along with the Company's SEC Reports
(as defined below) contain any untrue statement of a material fact nor omit to
state a material fact necessary in order to make the statements contained herein
or therein, in light of the circumstances in which they are made, not
misleading. Any financial projections and other estimates provided to the
Purchaser by the Company were based on the Company's experience in the industry
and on assumptions of fact and opinion as to future events which the Company, at
the date of the issuance of such projections or estimates, believed to be
reasonable.

            4.20 Insurance. The Company has general commercial, product
liability, fire and casualty insurance policies with coverages which the Company
believes are customary for companies similarly situated to the Company in the
same or similar business.

            4.21 SEC Reports. Except as set forth on Schedule 4.21, the Company
has filed all proxy statements, reports and other documents required to be filed
by it under the Securities Exchange Act 1934, as amended (the "Exchange Act").
The Company has furnished or otherwise made available to the Purchaser copies
of: (i) its Annual Report on Form 10-K for the fiscal year ended December 31,
2003; and (ii) its Quarterly Reports on Form 10-Q for the fiscal quarters ended
March 31, 2004 and June 30, 2004, and the Form 8-K filings which it has made
during the fiscal year 2004 to date (collectively, the "SEC Reports"). Except as
set forth on Schedule 4.21, each SEC Report was, at the time of its filing, in
substantial compliance with the requirements of its respective form and none of
the SEC Reports, nor the financial statements (and the notes thereto) included
in the SEC Reports, as of their respective filing dates, contained any untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading.

            4.22 Listing. The Company's Common Stock is traded on the NASD Over
the Counter Bulletin Board ("OTCBB") and satisfies all requirements for the
continuation of such trading. The Company has not received any notice that its
Common Stock will be ineligible to trade on the OTCBB or that its Common Stock
does not meet all requirements for such trading.

            4.23 No Integrated Offering. Neither the Company, nor any of its
affiliates, nor any person acting on its or their behalf, has directly or
indirectly made any offers or sales of any security or solicited any offers to
buy any security under circumstances that would cause the offering of the
Securities pursuant to this Agreement or any Related Agreement to be integrated
with prior offerings by the Company for purposes of the Securities Act which
would prevent the Company from selling the Securities pursuant to Rule 506 under
the Securities Act, or any applicable exchange-related stockholder approval
provisions, nor will the Company or any of its affiliates or subsidiaries take
any action or steps that would cause the offering of the Securities to be
integrated with other offerings.

            4.24 Stop Transfer. The Securities are restricted securities as of
the date of this Agreement. The Company will not issue any stop transfer order
or other order impeding the sale and delivery of any of the Securities at such
time as the Securities are registered for public sale or an exemption from
registration is available, except as required by state and federal securities
laws.

<PAGE>

            4.25 Dilution. The Company specifically acknowledges that its
obligation to issue the shares of Common Stock upon conversion of the Note and
exercise of the Warrant is binding upon the Company and enforceable regardless
of the dilution such issuance may have on the ownership interests of other
shareholders of the Company.

            4.26 Patriot Act. The Company certifies that, to the best of
Company's knowledge, the Company has not been designated, and is not owned or
controlled, by a "suspected terrorist" as defined in Executive Order 13224. The
Company hereby acknowledges that the Purchaser seeks to comply with all
applicable laws concerning money laundering and related activities. In
furtherance of those efforts, the Company hereby represents, warrants and agrees
that: (i) none of the cash or property that the Company will pay or will
contribute to the Purchaser has been or shall be derived from, or related to,
any activity that is deemed criminal under United States law; and (ii) no
contribution or payment by the Company to the Purchaser, to the extent that they
are within the Company's control shall cause the Purchaser to be in violation of
the United States Bank Secrecy Act, the United States International Money
Laundering Control Act of 1986 or the United States International Money
Laundering Abatement and Anti-Terrorist Financing Act of 2001. The Company shall
promptly notify the Purchaser if any of these representations ceases to be true
and accurate regarding the Company. The Company agrees to provide the Purchaser
any additional information regarding the Company that the Purchaser reasonably
deems necessary to ensure compliance with all applicable laws concerning money
laundering and similar activities. The Company understands and agrees that if at
any time it is discovered that any of the foregoing representations are
incorrect, or if otherwise required by applicable law or regulation related to
money laundering similar activities, the Purchaser may undertake appropriate
actions to ensure compliance with applicable law or regulation, including but
not limited to segregation and/or redemption of the Purchaser's investment in
the Company. The Company further understands that the Purchaser may release
confidential information about the Company and, if applicable, any underlying
beneficial owners, to proper authorities if the Purchaser, in its sole
discretion, determines that it is required to be disclosed by the Purchaser in
light of relevant rules and regulations under the laws set forth in subsection
(ii) above.

      5. Representations and Warranties of the Purchaser. The Purchaser hereby
represents and warrants to the Company as follows (such representations and
warranties do not lessen or obviate the representations and warranties of the
Company set forth in this Agreement)

            5.1 No Shorting. The Purchaser or any of its affiliates and
investment partners has not, will not and will not cause any person or entity,
to directly engage in "short sales" of the Company's Common Stock as long as the
Note shall be outstanding.

            5.2 Requisite Power and Authority. The Purchaser has all necessary
power and authority under all applicable provisions of law to execute and
deliver this Agreement and the Related Agreements and to carry out their
provisions. All corporate action on Purchaser's part required for the lawful
execution and delivery of this Agreement and the Related Agreements have been or
will be effectively taken prior to the Closing. Upon their execution and
delivery, this Agreement and the Related Agreements will be valid and binding
obligations of Purchaser, enforceable in accordance with their terms, except:

<PAGE>

            (a) as limited by applicable bankruptcy, insolvency, reorganization,
      moratorium or other laws of general application affecting enforcement of
      creditors' rights; and

            (b) as limited by general principles of equity that restrict the
      availability of equitable and legal remedies.

            5.3 Investment Representations. Purchaser understands that the
Securities are being offered and sold pursuant to an exemption from registration
contained in the Securities Act based in part upon Purchaser's representations
contained in the Agreement, including, without limitation, that the Purchaser is
an "accredited investor" within the meaning of Regulation D under the Securities
Act of 1933, as amended (the "Securities Act"). The Purchaser confirms that it
has received or has had full access to all the information it considers
necessary or appropriate to make an informed investment decision with respect to
the Note and the Warrant to be purchased by it under this Agreement and the Note
Shares and the Warrant Shares acquired by it upon the conversion of the Note and
the exercise of the Warrant, respectively. The Purchaser further confirms that
it has had an opportunity to ask questions and receive answers from the Company
regarding the Company's business, management and financial affairs and the terms
and conditions of the Offering, the Note, the Warrant and the Securities and to
obtain additional information (to the extent the Company possessed such
information or could acquire it without unreasonable effort or expense)
necessary to verify any information furnished to the Purchaser or to which the
Purchaser had access.

            5.4 Purchaser Bears Economic Risk. The Purchaser has substantial
experience in evaluating and investing in private placement transactions of
securities in companies similar to the Company so that it is capable of
evaluating the merits and risks of its investment in the Company and has the
capacity to protect its own interests. The Purchaser must bear the economic risk
of this investment until the Securities are sold pursuant to: (i) an effective
registration statement under the Securities Act; or (ii) an exemption from
registration is available with respect to such sale. Purchaser understands that
an investment in the Securities of the Company involves significant risks,
including those disclosed in the Company's SEC Reports, copies of which have
been provided to and reviewed by the Purchaser.

            5.5 Acquisition for Own Account. The Purchaser is acquiring the Note
and Warrant and the Note Shares and the Warrant Shares for the Purchaser's own
account for investment only, and not as a nominee or agent and not with a view
towards or for resale in connection with their distribution.

            5.6 Purchaser Can Protect Its Interest. The Purchaser represents
that by reason of its, or of its management's, business and financial
experience, the Purchaser has the capacity to evaluate the merits and risks of
its investment in the Note, the Warrant and the Securities and to protect its
own interests in connection with the transactions contemplated in this
Agreement, and the Related Agreements. Further, the Purchaser is aware of no
publication of any advertisement in connection with the transactions
contemplated in the Agreement or the Related Agreements.

<PAGE>

            5.7 Accredited Investor. Purchaser represents that it is an
accredited investor within the meaning of Regulation D under the Securities Act.

            5.8 Legends.

            (a) The Note shall bear substantially the following legend:

            "THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS
            NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
            AMENDED, OR ANY APPLICABLE, STATE SECURITIES LAWS. THIS NOTE AND THE
            COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE MAY NOT BE SOLD,
            OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN
            EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE OR SUCH SHARES
            UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF
            COUNSEL REASONABLY SATISFACTORY TO CARDIOGENESIS CORPORATION THAT
            SUCH REGISTRATION IS NOT REQUIRED."

            (b) The Note Shares and the Warrant Shares, if not issued by DWAC
      system (as hereinafter defined), shall bear a legend which shall be in
      substantially the following form until such shares are covered by an
      effective registration statement filed with the SEC:

            "THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
            UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE,
            STATE SECURITIES LAWS. THESE SHARES MAY NOT BE SOLD, OFFERED FOR
            SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
            REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT AND APPLICABLE
            STATE LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
            CARDIOGENESIS CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED."

            (c) The Warrant shall bear substantially the following legend:

            "THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS
            WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
            AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT
            AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT
            BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF
            AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT OR THE
            UNDERLYING SHARES OF COMMON STOCK UNDER SAID ACT

<PAGE>

            AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL
            REASONABLY SATISFACTORY TO CARDIOGENESIS CORPORATION THAT SUCH
            REGISTRATION IS NOT REQUIRED."

            5.9 Patriot Act. The Purchaser certifies that, to the best of
Purchaser's knowledge, the Purchaser has not been designated, and is not owned
or controlled, by a "suspected terrorist" as defined in Executive Order 13224.
The Purchaser hereby acknowledges that the Company seeks to comply with all
applicable laws concerning money laundering and related activities. In
furtherance of those efforts, the Purchaser hereby represents, warrants and
agrees that: (i) none of the cash or property that the Purchaser will pay or
will contribute to the Company has been or shall be derived from, or related to,
any activity that is deemed criminal under United States law; and (ii) no
contribution or payment by the Purchaser to the Company, to the extent that they
are within the Purchaser's control shall cause the Company to be in violation of
the United States Bank Secrecy Act, the United States International Money
Laundering Control Act of 1986 or the United States International Money
Laundering Abatement and Anti-Terrorist Financing Act of 2001. The Purchaser
shall promptly notify the Company if any of these representations ceases to be
true and accurate regarding the Purchaser. The Purchaser agrees to provide the
Company any additional information regarding the Purchaser that the Company
reasonably deems necessary to ensure compliance with all applicable laws
concerning money laundering and similar activities. The Purchaser understands
and agrees that if at any time it is discovered that any of the foregoing
representations are incorrect, or if otherwise required by applicable law or
regulation related to money laundering similar activities, the Company may
undertake appropriate actions to ensure compliance with applicable law or
regulation, including but not limited to segregation and/or redemption of the
Purchaser's investment in the Company. The Purchaser further understands that
the Company may release confidential information about the Purchaser and, if
applicable, any underlying beneficial owners, to proper authorities if the
Company, in its reasonable discretion, determines that such disclosure is
required in light of relevant rules and regulations under the laws set forth in
subsection (ii) above.

            5.10 Company Reliance. The Purchaser understands that the Securities
are being offered and sold to it in reliance on specific exemptions from the
registration requirements of United States federal and state securities laws and
that the Company is relying upon the truth and accuracy of, and the Purchaser's
compliance with, the representations, warranties, agreements, acknowledgments,
and understandings of the Purchaser set forth herein in order to determine the
availability of such exemptions and the eligibility of the Purchaser to acquire
the Securities.

      6. Covenants of the Company. The Company covenants and agrees with the
Purchaser as follows:

            6.1 Stop-Orders. The Company will advise the Purchaser, promptly
after it receives notice of issuance by the Securities and Exchange Commission
(the "SEC"), any state securities commission or any other regulatory authority
of any stop order or of any order preventing or suspending any offering of any
securities of the Company, or of the suspension of the qualification of the
Common Stock of the Company for offering or sale in any jurisdiction, or the
initiation of any proceeding for any such purpose.

            6.2 Listing. The Company will maintain the listing of its Common
Stock on the OTCBB, and will comply in all material respects with any and all
OTCBB and other securities reporting, filing and other obligations which are
applicable to the Company.

            6.3 Market Regulations. The Company shall notify the SEC, NASD and
applicable state authorities, in accordance with their requirements, of the
transactions contemplated by this Agreement, and shall take all other necessary
action and proceedings as may be required and permitted by applicable law, rule
and regulation, for the legal and valid issuance of the Securities to the
Purchaser and promptly provide copies thereof to the Purchaser.

            6.4 Reporting Requirements. The Company will timely file with the
SEC all reports required to be filed pursuant to the Exchange Act and refrain
from terminating its status as an issuer required by the Exchange Act to file
reports thereunder even if the Exchange Act or the rules or regulations
thereunder would permit such termination.

            6.5 Use of Funds. The Company agrees that it will use the proceeds
of the sale of the Note and Warrant for general working capital purposes only
(it being understood that $3,000,000 of the proceeds of the Note will be
deposited in the Restricted Account on the Closing Date and shall be subject to
the terms and conditions of the Restricted Account Agreement and the Restricted
Account Side Letter).

            6.6 Access to Facilities. The Company will permit any
representatives designated by the Purchaser (or any successor of the Purchaser),
upon reasonable notice and

<PAGE>

during normal business hours, at such person's expense and accompanied by a
representative of the Company, to:

            (a) visit and inspect any of the properties of the Company;

            (b) examine the corporate and financial records of the Company
      (unless such examination is not permitted by federal, state or local law
      or by contract) and make copies thereof or extracts therefrom; and

            (c) discuss the affairs, finances and accounts of the Company with
      the directors, officers and independent accountants of the Company.

Notwithstanding the foregoing, the Company will not provide any material,
non-public information to the Purchaser unless the Purchaser signs a
confidentiality agreement, in a form reasonably acceptable to the Company, and
otherwise complies with Regulation FD, under the federal securities laws.

            6.7 Taxes. The Company will promptly pay and discharge, or cause to
be paid and discharged, when due and payable, all lawful taxes, assessments and
governmental charges or levies imposed upon the income, profits, property or
business of the Company; provided, however, that any such tax, assessment,
charge or levy need not be paid if the validity thereof shall currently be
contested in good faith by appropriate proceedings and if the Company shall have
set aside on its books adequate reserves with respect thereto, and provided,
further, that the Company will pay all such taxes, assessments, charges or
levies forthwith upon the commencement of proceedings to foreclose any lien
which may have attached as security therefor.

            6.8 Insurance. The Company will keep its assets which are of an
insurable character insured by financially sound and reputable insurers against
loss or damage by fire, explosion and other risks customarily insured against by
companies in similar business similarly situated as the Company; and the Company
will maintain, with financially sound and reputable insurers, insurance against
other hazards and risks and liability to persons and property to the extent and
in the manner which the Company reasonably believes is customary for companies
in similar business similarly situated as the Company and to the extent
available on commercially reasonable terms. The Company and each of its
Subsidiaries will jointly and severally bear the full risk of loss from any loss
of any nature whatsoever with respect to the assets pledged to the Purchaser as
security for its obligations hereunder and under the Related Agreements. At the
Company's own cost and expense in amounts and with carriers reasonably
acceptable to Purchaser, the Company and each of the Subsidiaries shall (i) keep
all its insurable properties and properties in which it has an interest insured
against the hazards of fire, flood, sprinkler leakage, those hazards covered by
extended coverage insurance and such other hazards, and for such amounts, as is
customary in the case of companies engaged in businesses similar to the
Company's or the respective Subsidiary's including business interruption
insurance; (ii) maintain a bond in such amounts as is customary in the case of
companies engaged in businesses similar to the Company's or the Subsidiary's
insuring against larceny, embezzlement or other criminal misappropriation of
insured's officers and employees who may either singly or jointly with others at
any time have access to the assets or funds of the Company either directly or
through

<PAGE>

governmental authority to draw upon such funds or to direct generally the
disposition of such assets; (iii) maintain public and product liability
insurance against claims for personal injury, death or property damage suffered
by others; (iv) maintain all such worker's compensation or similar insurance as
may be required under the laws of any state or jurisdiction in which the Company
or the Subsidiary is engaged in business; and (v) furnish Purchaser with (x)
copies of all policies and evidence of the maintenance of such policies at least
thirty (30) days before any expiration date, (y) excepting the Company's
workers' compensation policy, endorsements to such policies naming Purchaser as
"co-insured" or "additional insured" and appropriate loss payable endorsements
in form and substance satisfactory to Purchaser, naming Purchaser as loss payee,
and (z) evidence that as to Purchaser the insurance coverage shall not be
impaired or invalidated by any act or neglect of the Company or any Subsidiary
and the insurer will provide Purchaser with at least thirty (30) days notice
prior to cancellation. The Company and each Subsidiary shall instruct the
insurance carriers that in the event of any loss thereunder, the carriers shall
make payment for such loss to the Company and/or the Subsidiary and Purchaser
jointly.

            6.9 Intellectual Property. The Company shall maintain in full force
and effect its corporate existence, rights and franchises and all licenses and
other rights to use Intellectual Property owned or possessed by it and
reasonably deemed to be necessary to the conduct of its business.

            6.10 Properties. The Company will keep its properties in good
repair, working order and condition, reasonable wear and tear excepted, and from
time to time make all needful and proper repairs, renewals, replacements,
additions and improvements thereto; and the Company will at all times comply
with each provision of all leases to which it is a party or under which it
occupies property if the breach of such provision could reasonably be expected
to have a Material Adverse Effect.

            6.11 Confidentiality. The Company agrees that it will not disclose,
and will not include in any public announcement, the name of the Purchaser,
unless expressly agreed to by the Purchaser or unless and until such disclosure
is required by law or applicable regulation, and then only to the extent of such
requirement, provided that the Purchaser acknowledges and agrees that its
identity will be disclosed in the Form 8-K that will be filed by the Company in
connection herewith, and in the copies of this Agreement and the Related
Agreements that are attached as Exhibits to various SEC Reports of the Company.
The Company may disclose Purchaser's identity and the terms of this Agreement to
its current and prospective debt and equity financing sources.

            6.12 Required Approvals. For so long as twenty-five percent (25%) of
the principal amount of the Note is outstanding, the Company, without the prior
written consent of the Purchaser, shall not:

            (a) (i) directly or indirectly declare or pay any dividends, other
      than (x) dividends paid to the Company or any of its wholly-owned
      Subsidiaries (ii) issue any preferred stock that is mandatorily redeemable
      prior to the Maturity Date (as defined in the Note) (other than pursuant
      to the Company's existing Rights Plan) or (iii) redeem any

<PAGE>

      of its preferred stock or other equity interests (other than pursuant to
      the Company's existing Rights Plan);

            (b) liquidate, dissolve or effect a material reorganization (it
      being understood that in no event shall the Company dissolve, liquidate or
      merge with any other person or entity (unless the Company is the surviving
      entity) or (ii) if the Company is not the surviving entity, (A) the
      successor entity is solvent and agrees to assume all of the obligations of
      the Company under this Agreement and the Related Agreements or (B) the
      consideration per share of the Company's Common Stock exceed the then
      effective Fixed Conversion Price;

            (c) become subject to (including, without limitation, by way of
      amendment to or modification of) any agreement or instrument which by its
      terms would (under any circumstances) restrict the Company's right to
      perform the provisions of this Agreement or any of the Related Agreements;

            (d) materially alter or change the scope of the business of the
      Company;

            (e) (i) create, incur, assume or suffer to exist any indebtedness,
      other than (A) trade debt arising in the ordinary course of business, (B)
      debt incurred to finance the purchase of inventory and equipment not in
      excess of $1,500,000 in the aggregate for any twelve (12) month period,
      (C) any subordinated unsecured indebtedness less than $5,000,000 in the
      aggregate, (D) the Company's indebtedness to the Purchaser, (E)
      indebtedness set forth on Schedule 6.12(e) attached hereto and made a part
      hereof and any refinancings or replacements thereof on terms no less
      favorable to the Purchaser than the debt being refinanced or replaced, (F)
      any indebtedness incurred in connection with the purchase of assets in the
      ordinary course of business, and any refinancings or replacements thereof
      on terms no less favorable to the Purchaser than the indebtedness being
      refinanced or replaced; and (G) any unsecured or unsecured indebtedness
      expressly subordinated (on such terms as shall be satisfactory to the
      Purchaser in its reasonable discretion) to the indebtedness owed by the
      Company to the Purchaser that is incurred in connection with (1) the
      acquisition of another company, (2) a product launch for the Company's
      products, (3) research and development of any new Company products and (4)
      research projects that focus on the science of the Company's existing
      products; (ii) cancel any indebtedness owing to it in excess of $50,000 in
      the aggregate during any 12 month period; (iii) assume, guarantee, endorse
      or otherwise become directly or contingently liable in connection with any
      obligations of any other Person, except the endorsement of negotiable
      instruments by the Company for deposit or collection or similar
      transactions in the ordinary course of business; and

            (f) make investments in, make any loans or advances to, or transfer
      assets to, any of its Subsidiaries, other than any immaterial investments,
      loans, advances and/or asset transfers made in the ordinary course of
      business, provided however, that the Company shall not be restricted from
      winding up and dissolving inactive Subsidiaries..

            6.13 Reissuance of Securities. Subject to receipt from the Purchaser
(or any other holder of the Securities) of appropriate and customary factual
representations or

<PAGE>

conformations necessary to assure compliance with applicable securities law, the
Company agrees to reissue certificates representing the Securities without the
legends set forth in Section 5.8 above at such time as:

            (a) the holder thereof is permitted to dispose of such Securities
      pursuant to Rule 144(k) under the Securities Act; or

            (b) upon resale subject to an effective registration statement after
      such Securities are registered under the Securities Act.

The Company agrees to cooperate with the Purchaser in connection with all
resales pursuant to Rule 144(d) and Rule 144(k) and provide legal opinions
necessary to allow such resales provided the Company and its counsel receive
reasonably requested representations from the selling Purchaser and broker, if
any.

            6.14 Opinion. On the Closing Date, the Company will deliver to the
Purchaser an opinion from the Company's legal counsel in the form attached
hereto as Exhibit C. The Company will provide, at the Company's expense, such
other legal opinions in the future as are reasonably necessary for the
conversion of the Note and exercise of the Warrant so long as the Company and
its counsel receive reasonably requested representations from the selling
Purchaser or holder.

            6.15 Margin Stock. The Company will not permit any of the proceeds
of the Note or the Warrant to be used directly or indirectly to "purchase" or
"carry" "margin stock" or to repay indebtedness incurred to "purchase" or
"carry" "margin stock" within the respective meanings of each of the quoted
terms under Regulation U of the Board of Governors of the Federal Reserve System
as now and from time to time hereafter in effect.

            6.16 Restricted Cash Disclosure. The Company agrees that, in
connection with its filing of its 8-K Report with the SEC concerning the
transactions contemplated by this Agreement and the Related Agreements (such
report, the "Laurus Transaction 8-K") in a timely manner after the date hereof,
it will disclose in such Laurus Transaction 8-K the amount of the proceeds of
the Note issued to the Purchaser that has been placed in a restricted cash
account and is subject to the terms and conditions of this Agreement and the
Related Agreements. Furthermore, the Company agrees to disclose in all public
filings required by the Commission (where appropriate) following the filing of
the Laurus Transaction 8-K, the existence of the restricted cash referred to in
the immediately preceding sentence, together with the amount thereof.

            6.17 Financing Right of First Refusal. (a) The Company hereby grants
to the Purchaser a right of first refusal to provide any Additional Financing
(as defined below) to be issued by the Company and/or any of its Subsidiaries,
subject to the following terms and conditions. From and after the date hereof,
prior to the incurrence of any additional indebtedness and/or the sale or
issuance of any equity interests of the Company or any of its Subsidiaries for
cash (an "Additional Financing"), the Company and/or any Subsidiary of the
Company, as the case may be, shall notify the Purchaser of its intention to
enter into such Additional Financing. In

<PAGE>

connection therewith, the Company and/or the applicable Subsidiary thereof shall
submit a fully executed term sheet (a "Proposed Term Sheet") to the Purchaser
setting forth the terms, conditions and pricing of any such Additional Financing
(such financing to be negotiated on "arm's length" terms and the terms thereof
to be negotiated in good faith) proposed to be entered into by the Company
and/or such Subsidiary. The Purchaser shall have the right, but not the
obligation, to deliver its own written proposed term sheet (the "Purchaser Term
Sheet") setting forth the terms and conditions upon which Purchaser would be
willing to provide such Additional Financing to the Company and/or such
Subsidiary. The Purchaser Term Sheet shall contain terms no less favorable to
the Company and/or such Subsidiary than those outlined in Proposed Term Sheet.
The Purchaser shall deliver such Purchaser Term Sheet within five (5) business
days of receipt of each such Proposed Term Sheet. If the provisions of the
Purchaser Term Sheet are at least as favorable to the Company and/or such
Subsidiary, as the case may be, as the provisions of the Proposed Term Sheet, as
determined by each of the Purchaser and the Company in their reasonable
discretion, the Company and/or such Subsidiary shall enter into and consummate
the Additional Financing transaction outlined in the Purchaser Term Sheet.

            (b) The Company will not, and will not permit its Subsidiaries to,
agree, directly or indirectly, to any restriction with any person or entity
which restricts the Purchaser from consummating an Additional Financing with the
Company or any of its Subsidiaries.

            (c) Notwithstanding anything to the contrary herein, this Section
6.17 shall not apply to the following: (i) the granting of options or restricted
stock to employees, officers, directors and key consultants of the Company
pursuant to any stock option plan or agreement duly adopted by the Company's
board of directors by vote of a majority of the independent members of the board
or a committee of independent directors established for such purpose, or (ii)
the exercise of any security issued by the Company in connection with the offer
and sale of the Company's securities pursuant to this Agreement, or (iii) the
exercise of or conversion of any convertible securities, options or warrants
issued and outstanding on the date hereof, provided such securities have not
been amended since the date hereof, or (iv) the issuance of securities in
connection with a joint venture or development agreement or strategic
partnership or similar agreement approved by the Company's board of directors,
no significant purpose of which is to raise equity capital, or (v) the issuance
of securities in connection with an equipment lease financing transaction or a
bank financing transaction approved by the Company's board of directors, no
significant purpose of which is to raise equity capital; (vi) the issuance of
any class of the Company's non-convertible common stock or non-convertible
preferred stock in connection with an acquisition of another business
enterprise, or the granting of options or restricted stock to employees,
officers, directors and key consultants of the target company in connection with
such an acquisition; or (vi) the exercise of or conversion of any convertible
securities, options or warrants issued and outstanding pursuant to subclauses
(i), (iv) and (v) above.

            6.18 Additional Investment. The Company agrees that the Purchaser
shall have the right (at its sole option), on or prior to the date which is 120
days following the Closing Date, to issue an additional note to the Company in
an aggregate principal amount of up to $2,000,000

<PAGE>

on the same terms and conditions (including, without limitation, the same
interest rate, the Fixed Conversion Price (as defined in the Note) then in
effect, proportionate warrant coverage (at the same exercise prices), a
proportionate amortization schedule, etc.) set forth in, and pursuant to
substantially similar documentation as, this Agreement and the Related
Agreements, provided that all such additional principal shall be disbursed
directly to the Company, and none of such additional principal shall be placed
in a restricted account.

      7. Covenants of the Purchaser. The Purchaser covenants and agrees with the
Company as follows:

            7.1 Confidentiality. The Purchaser agrees that it will not disclose,
and will not include in any public announcement, the name of the Company, unless
expressly agreed to by the Company or unless and until such disclosure is
required by law or applicable regulation, and then only to the extent of such
requirement.

            7.2 Non-Public Information. The Purchaser agrees not to effect any
sales or voluntary purchases in the shares of the Company's Common Stock while
in possession of material, non-public information regarding the Company if such
sales or voluntary purchases would violate applicable securities law, it being
expressly acknowledged and understood that no conversion of the Note effected
will result in a breach of this covenant by the Purchaser.

            7.3 No Shorting. The Purchaser represents, warrants, covenants and
agrees that neither the Purchaser nor any of its affiliates or investment
partners (i) has or, for so long as any portion of the Note shall be
outstanding, will directly or indirectly engage in any "short sales" of or using
the Company's Common Stock, or (ii) has or, for so long as any portion of the
Note shall be outstanding, will cause any person or entity to directly or
instruct any person or entity to engage in "short sales" or other hedging
transactions relating to the Company's Common Stock. To the extent that
Purchaser or its affiliates or investment partners engage in any such short
sales or hedging transactions following repayment or conversion in full of the
Note, such transactions shall only be effected in accordance with Rule 10a-1
under the Exchange Act, to the extent applicable.

      8. Covenants of the Company and Purchaser Regarding Indemnification.

            8.1 Company Indemnification. The Company agrees to indemnify, hold
harmless, reimburse and defend Purchaser, each of Purchaser's officers,
directors, agents, affiliates, control persons, and principal shareholders,
against any claim, cost, expense, liability, obligation, loss or damage
(including reasonable legal fees) of any nature, incurred by or imposed upon the
Purchaser which results, arises out of or is based upon: (i) any
misrepresentation by Company or breach of any warranty by Company in this
Agreement, any Related Agreement or in any exhibits or schedules attached hereto
or thereto; or (ii) any breach or default in performance by Company of any
covenant or undertaking to be performed by Company hereunder, or any other
agreement entered into by the Company and Purchaser relating hereto.

            8.2 Purchaser's Indemnification. Purchaser agrees to indemnify, hold
harmless, reimburse and defend the Company and each of the Company's officers,
directors,

<PAGE>

agents, affiliates, control persons and principal shareholders, at all times
against any claim, cost, expense, liability, obligation, loss or damage
(including reasonable legal fees) of any nature, incurred by or imposed upon the
Company which results, arises out of or is based upon: (i) any misrepresentation
by Purchaser or breach of any warranty by Purchaser in this Agreement or in any
exhibits or schedules attached hereto or any Related Agreement; or (ii) any
breach or default in performance by Purchaser of any covenant or undertaking to
be performed by Purchaser hereunder, or any other agreement entered into by the
Company and Purchaser relating hereto.

      9. Conversion of Convertible Note.

            9.1 Mechanics of Conversion.

            (a) Provided the Purchaser has notified the Company of the
      Purchaser's intention to sell the Note Shares and the Note Shares are
      included in an effective registration statement or are otherwise exempt
      from registration when sold: (i) Upon the conversion of the Note or part
      thereof, the Company shall, at its own cost and expense, take all
      necessary action (including the issuance of an opinion of counsel
      reasonably acceptable to the Purchaser following a request by the
      Purchaser) to assure that the Company's transfer agent shall issue shares
      of the Company's Common Stock in the name of the Purchaser (or its
      nominee) or such other persons as designated by the Purchaser in
      accordance with Section 9.1(b) hereof and in such denominations to be
      specified representing the number of Note Shares issuable upon such
      conversion; and (ii) The Company warrants that no instructions other than
      these instructions have been or will be given to the transfer agent of the
      Company's Common Stock and that after the Effectiveness Date (as defined
      in the Registration Rights Agreement) the Note Shares issued will be
      freely transferable subject to the prospectus delivery requirements of the
      Securities Act and the provisions of this Agreement, and will not contain
      a legend restricting the resale or transferability of the Note Shares.

            (b) Purchaser will give notice of its decision to exercise its right
      to convert the Note or part thereof by telecopying or otherwise delivering
      an executed and completed notice of the number of shares to be converted
      to the Company (the "Notice of Conversion"). The Purchaser will not be
      required to surrender the Note until the Purchaser receives a credit to
      the account of the Purchaser's prime broker through the DWAC system (as
      defined below), representing the Note Shares or until the Note has been
      fully satisfied. Each date on which a Notice of Conversion is telecopied
      or delivered to the Company in accordance with the provisions hereof shall
      be deemed a "Conversion Date." Pursuant to the terms of the Notice of
      Conversion, the Company will issue instructions to the transfer agent
      accompanied by an opinion of counsel within three (3) business days of the
      date of the delivery to the Company of the Notice of Conversion and shall
      cause the transfer agent to transmit the certificates representing the
      Conversion Shares to the Holder by crediting the account of the
      Purchaser's prime broker with the Depository Trust Company ("DTC") through
      its Deposit Withdrawal Agent Commission ("DWAC") system within three (3)
      business days after receipt by the Company of the Notice of Conversion
      (the "Delivery Date").

<PAGE>

            (c) The Company understands that a delay in the delivery of the Note
      Shares in the form required pursuant to Section 9 hereof beyond the
      Delivery Date could result in economic loss to the Purchaser. In the event
      that, through no fault of the Purchaser, the Company fails to direct its
      transfer agent to deliver the Note Shares to the Purchaser via the DWAC
      system within the time frame set forth in Section 9.1(b) above and the
      Note Shares are not delivered to the Purchaser by the Delivery Date, as
      compensation to the Purchaser for such loss, the Company agrees to pay
      late payments to the Purchaser for late issuance of the Note Shares in the
      form required pursuant to Section 9 hereof upon conversion of the Note in
      the amount equal to the greater of: (i) $500 per business day after the
      Delivery Date; or (ii) the Purchaser's actual damages from such delayed
      delivery. Notwithstanding the foregoing, the Company will not owe the
      Purchaser any late payments if the delay in the delivery of the Note
      Shares beyond the Delivery Date is solely out of the control of the
      Company and the Company is actively trying to cure the cause of the delay.
      The Company shall pay any payments incurred under this Section in
      immediately available funds upon demand and, in the case of actual
      damages, accompanied by reasonable documentation of the amount of such
      damages. Such documentation shall show the number of shares of Common
      Stock the Purchaser is forced to purchase (in an open market transaction)
      which the Purchaser anticipated receiving upon such conversion, and shall
      be calculated as the amount by which (A) the Purchaser's total purchase
      price (including customary brokerage commissions, if any) for the shares
      of Common Stock so purchased exceeds (B) the aggregate principal and/or
      interest amount of the Note, for which such Conversion Notice was not
      timely honored.

Nothing contained herein or in any document referred to herein or delivered in
connection herewith shall be deemed to establish or require the payment of a
rate of interest or other charges in excess of the maximum permitted by
applicable law. In the event that the rate of interest or dividends required to
be paid or other charges hereunder exceed the maximum amount permitted by such
law, any payments in excess of such maximum shall be credited against amounts
owed by the Company to a Purchaser and thus refunded to the Company.

      10. Registration Rights.

            10.1 Registration Rights Granted. The Company hereby grants
registration rights to the Purchaser pursuant to a Registration Rights Agreement
dated as of even date herewith between the Company and the Purchaser.

            10.2 Offering Restrictions. Except as previously disclosed in the
SEC Reports or in the Exchange Act Filings, or stock or stock options granted to
employees or directors of the Company (these exceptions hereinafter referred to
as the "Excepted Issuances") prior to the full repayment or conversion of the
Note (together with all accrued and unpaid interest and fees related thereto
(the "Exclusion Period"), the Company will not except with Purchaser's prior
written consent (such consent not to be unreasonably withheld), issue any (i)
debt securities with a continuously variable/floating conversion feature which
are or could be (by conversion or registration) free-trading securities (i.e.
common stock subject to a registration statement), or (ii) any equity securities
with a continuously variable/floating conversion feature which are or could be
(by conversion or registration) free-trading securities (i.e. common stock
subject to a registration statement), provided that no consent shall be
necessary on the issuance of equity

<PAGE>

securities having such a variable/floating conversion feature where the
conversion price is subject to a minimum price per share below the lesser of (i)
$0.20 and (ii) forty percent (40%) of the average trading price of the Company's
common stock for the ten (10) trading days immediately preceding such subsequent
financing, which equity securities may not be converted or otherwise exchanged
for shares of the Company's common stock.

      11. Miscellaneous.

            11.1 Governing Law. THIS AGREEMENT AND EACH RELATED AGREEMENT SHALL
BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS. ANY ACTION BROUGHT BY
EITHER PARTY AGAINST THE OTHER CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS
AGREEMENT AND EACH RELATED AGREEMENT SHALL BE BROUGHT ONLY IN THE STATE COURTS
OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK. BOTH
PARTIES AND THE INDIVIDUALS EXECUTING THIS AGREEMENT AND THE RELATED AGREEMENTS
ON BEHALF OF THE COMPANY AGREE TO SUBMIT TO THE JURISDICTION OF SUCH COURTS AND
WAIVE TRIAL BY JURY. IN THE EVENT THAT ANY PROVISION OF THIS AGREEMENT OR ANY
RELATED AGREEMENT DELIVERED IN CONNECTION HEREWITH IS INVALID OR UNENFORCEABLE
UNDER ANY APPLICABLE STATUTE OR RULE OF LAW, THEN SUCH PROVISION SHALL BE DEEMED
INOPERATIVE TO THE EXTENT THAT IT MAY CONFLICT THEREWITH AND SHALL BE DEEMED
MODIFIED TO CONFORM WITH SUCH STATUTE OR RULE OF LAW. ANY SUCH PROVISION WHICH
MAY PROVE INVALID OR UNENFORCEABLE UNDER ANY LAW SHALL NOT AFFECT THE VALIDITY
OR ENFORCEABILITY OF ANY OTHER PROVISION OF THIS AGREEMENT OR ANY RELATED
AGREEMENT.

            11.2 Survival. The representations, warranties, covenants and
agreements made herein shall survive any investigation made by the Purchaser and
the closing of the transactions contemplated hereby to the extent provided
therein. All statements as to factual matters contained in any certificate or
other instrument delivered by or on behalf of the Company pursuant hereto in
connection with the transactions contemplated hereby shall be deemed to be
representations and warranties by the Company hereunder solely as of the date of
such certificate or instrument.

            11.3 Successors. Except as otherwise expressly provided herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the
successors, heirs, executors and administrators of the parties hereto and shall
inure to the benefit of and be enforceable by each person who shall be a holder
of the Securities from time to time, other than the holders of Common Stock
which has been sold by the Purchaser pursuant to Rule 144 or an effective
registration statement. Purchaser may not assign its rights hereunder to a
competitor of the Company.

            11.4 Entire Agreement. This Agreement, the Related Agreements, the
exhibits and schedules hereto and thereto and the other documents delivered
pursuant hereto constitute the full and entire understanding and agreement
between the parties with regard to the subjects

<PAGE>

hereof and no party shall be liable or bound to any other in any manner by any
representations, warranties, covenants and agreements except as specifically set
forth herein and therein.

            11.5 Severability. In case any provision of the Agreement shall be
invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby.

            11.6 Amendment and Waiver.

            (a) This Agreement may be amended or modified only upon the written
      consent of the Company and the Purchaser.

            (b) The obligations of the Company and the rights of the Purchaser
      under this Agreement may be waived only with the written consent of the
      Purchaser.

            (c) The obligations of the Purchaser and the rights of the Company
      under this Agreement may be waived only with the written consent of the
      Company.

            11.7 Delays or Omissions. It is agreed that no delay or omission to
exercise any right, power or remedy accruing to any party, upon any breach,
default or noncompliance by another party under this Agreement or the Related
Agreements, shall impair any such right, power or remedy, nor shall it be
construed to be a waiver of any such breach, default or noncompliance, or any
acquiescence therein, or of or in any similar breach, default or noncompliance
thereafter occurring. All remedies, either under this Agreement, or the Related
Agreements, by law or otherwise afforded to any party, shall be cumulative and
not alternative.

            11.8 Notices. All notices required or permitted hereunder shall be
in writing and shall be deemed effectively given:

            (a) upon personal delivery to the party to be notified;

            (b) when sent by confirmed facsimile if sent during normal business
      hours of the recipient, if not, then on the next business day;

            (c) three (3) business days after having been sent by registered or
      certified mail, return receipt requested, postage prepaid; or

            (d) one (1) day after deposit with a nationally recognized overnight
      courier, specifying next day delivery, with written verification of
      receipt.

All communications shall be sent as follows:

           If to the Company, to:       CARDIOGENESIS CORPORATION
                                        26632 Towne Center Drive
                                        Suite 320
                                        Foothill Ranch, CA 92610

                                        Attention: Chief Financial Officer

<PAGE>

                                        Facsimile: 714-649-5102

                                        with a copy to:

                                        Jeffer Mangels Butler & Marmaro LLP
                                        1900 Avenue of the Stars, Seventh Floor
                                        Los Angeles, CA 90067
                                        Attention:Robert M. Steinberg, Esq.
                                        Facsimile:(310) 203-0567

           If to the Purchaser, to:     Laurus Master Fund, Ltd.
                                        c/o M&C Corporate Services Limited
                                        P.O. Box 309 GT
                                        Ugland House, George Town
                                        South Church Street
                                        Grand Cayman, Cayman Islands
                                        Facsimile: 345-949-8080

                                        with a copy to:

                                        John E. Tucker , Esq.
                                        825 Third Avenue 14th Floor
                                        New York, NY 10022
                                        Facsimile: 212-541-4434

or at such other address as the Company or the Purchaser may designate by
written notice to the other parties hereto given in accordance herewith.

            11.9 Attorneys' Fees. In the event that any suit or action is
instituted to enforce any provision in this Agreement, the prevailing party in
such dispute shall be entitled to recover from the losing party all fees, costs
and expenses of enforcing any right of such prevailing party under or with
respect to this Agreement, including, without limitation, such reasonable fees
and expenses of attorneys and accountants, which shall include, without
limitation, all fees, costs and expenses of appeals.

            11.10 Titles and Subtitles. The titles of the sections and
subsections of the Agreement are for convenience of reference only and are not
to be considered in construing this Agreement.

            11.11 Facsimile Signatures; Counterparts. This Agreement may be
executed by facsimile signatures and in any number of counterparts, each of
which shall be an original, but all of which together shall constitute one
instrument.

            11.12 Broker's Fees. Except as set forth on Schedule 11.12 hereof,
Each party hereto represents and warrants that no agent, broker, investment
banker, person or firm acting on behalf of or under the authority of such party
hereto is or will be entitled to any broker's or finder's fee or any other
commission directly or indirectly in connection with the transactions

<PAGE>

contemplated herein. Each party hereto further agrees to indemnify each other
party for any claims, losses or expenses incurred by such other party as a
result of the representation in this Section 11.12 being untrue.

            11.13 Construction. Each party acknowledges that its legal counsel
participated in the preparation of this Agreement and the Related Agreements
and, therefore, stipulates that the rule of construction that ambiguities are to
be resolved against the drafting party shall not be applied in the
interpretation of this Agreement to favor any party against the other.

             [THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK

<PAGE>

           IN WITNESS WHEREOF, the parties hereto have executed the SECURITIES
PURCHASE AGREEMENT as of the date set forth in the first paragraph hereof.

COMPANY:                                    PURCHASER:

CARDIOGENESIS CORPORATION                   LAURUS MASTER FUND, LTD.

By: __________________________              By:________________________________
Name:_________________________              Name:______________________________
Title:________________________              Title:_____________________________

<PAGE>

                                    EXHIBIT A

                            FORM OF CONVERTIBLE NOTE

<PAGE>

                                    EXHIBIT B

                                 FORM OF WARRANT

<PAGE>

                                    EXHIBIT C

                                 FORM OF OPINION

           Please see attached.

<PAGE>

                                    EXHIBIT D

                            FORM OF ESCROW AGREEMENT